Profile data is unavailable for this security.
About the company
Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedic’s product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Company’s offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
- Revenue in NOK (TTM)565.36m
- Net income in NOK-23.54m
- Incorporated2002
- Employees45.00
- LocationNavamedic ASAHenrik Ibsens gate 100OSLO 0255NorwayNOR
- Phone+47 67112540
- Fax+47 67112541
- Websitehttps://navamedic.com/
More ▼
Mergers & acquisitions
| Acquired company | NAVA:OSL since announced | Transaction value |
|---|---|---|
| Dne Pharma AS | 2.66% | 22.34m |
Data delayed at least 15 minutes, as of Mar 02 2026.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IRLAB Therapeutics AB | 60.53m | -115.89m | 153.58m | 31.00 | -- | 4.75 | -- | 2.54 | -1.75 | -1.75 | 0.8494 | 0.3617 | 0.4188 | -- | 11.05 | 1,853,613.00 | -80.18 | -31.73 | -328.93 | -40.78 | -72.94 | -33.99 | -191.45 | -101.39 | -- | -5.62 | 0.4937 | -- | -39.28 | -- | -32.34 | -- | -- | -- |
| Magle Chemoswed Holding AB | 308.06m | -28.02m | 174.02m | 144.00 | -- | 0.3107 | 5.96 | 0.5649 | -1.29 | -1.29 | 14.56 | 25.75 | 0.3085 | -0.0596 | 8.14 | 1,989,374.00 | -2.81 | 2.43 | -3.45 | 3.45 | 102.66 | 88.63 | -9.09 | 4.76 | 0.8205 | -0.1043 | 0.3887 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
| Isofol Medical AB (publ) | 0.00 | -57.06m | 210.25m | 6.00 | -- | -- | -- | -- | -0.246 | -0.246 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -50.03 | -- | -64.52 | -- | -- | -- | -1,377.23 | -- | -- | -- | -- | -- | -- | -24.56 | -- | -- | -- |
| Elicera Therapeutics AB | 11.44m | -18.34m | 315.46m | 2.00 | -- | 12.82 | -- | 27.59 | -0.4128 | -0.4128 | 0.2696 | 0.4813 | 0.3948 | -- | 5.80 | 5,427,590.00 | -63.31 | -46.13 | -78.88 | -59.33 | -- | -- | -160.35 | -270.46 | -- | -- | -- | -- | 52.28 | -- | -8.05 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -80.45m | 324.01m | 6.00 | -- | -- | -- | -- | -3.60 | -3.60 | 0.00 | -1.33 | 0.00 | -- | -- | 0.00 | -179.79 | -146.87 | -660.20 | -220.28 | -- | -- | -- | -1,379,275.00 | -- | -39.82 | 3.77 | -- | -- | -- | -49.32 | -- | -- | -- |
| Biohit Oyj | 176.43m | 30.34m | 340.62m | 46.00 | 13.95 | 2.53 | 8.91 | 1.93 | 0.1778 | 0.1778 | 1.03 | 0.9804 | 0.8895 | 5.36 | 4.61 | 341,304.30 | 15.86 | 9.67 | 19.52 | 12.32 | 68.79 | 65.69 | 17.83 | 9.82 | 2.31 | -- | 0.097 | 0.00 | 9.92 | 17.12 | 5.14 | -- | 109.13 | -- |
| Corline Biomedical AB | 8.06m | -15.50m | 427.67m | 12.00 | -- | 4.33 | -- | 53.06 | -0.5929 | -0.5929 | 0.3093 | 3.66 | 0.0792 | -- | 5.89 | 637,583.30 | -15.22 | -9.29 | -16.29 | -10.07 | 81.36 | 109.32 | -192.31 | -60.64 | -- | -- | -- | -- | -21.73 | 15.66 | 36.56 | -- | -35.49 | -- |
| Enzymatica AB (publ) | 56.78m | -54.66m | 501.18m | 20.00 | -- | 3.83 | -- | 8.83 | -0.2138 | -0.2138 | 0.2221 | 0.5116 | 0.3197 | 1.17 | 4.88 | 2,695,150.00 | -30.78 | -33.41 | -33.37 | -38.75 | 61.45 | 61.39 | -96.27 | -104.78 | -- | -108.60 | 0.0082 | -- | 18.27 | -13.49 | 2.42 | -- | -45.57 | -- |
| Navamedic ASA | 565.36m | -23.54m | 525.19m | 45.00 | -- | 1.57 | 67.18 | 0.929 | -1.11 | -1.11 | 26.97 | 13.93 | 0.9351 | 3.48 | 8.28 | -- | -3.89 | -0.5784 | -5.27 | -0.8691 | 38.97 | 39.81 | -4.16 | -0.5578 | 0.887 | 0.4484 | 0.384 | -- | 6.38 | 21.92 | -329.13 | -- | -- | -- |
| Moberg Pharma AB (publ) | 14.26m | -28.69m | 531.11m | 5.00 | -- | 0.7313 | -- | 37.24 | -0.5809 | -0.5809 | 0.289 | 14.15 | 0.0195 | 1.49 | 4.58 | 2,707,600.00 | -3.92 | -11.42 | -4.02 | -11.95 | 56.73 | -- | -201.18 | -1,423.72 | 14.49 | -- | 0.0038 | -- | 37.99 | -- | 89.32 | -- | -- | -- |
| Dicot Pharma AB | 210.69k | -84.38m | 631.84m | 4.00 | -- | 8.17 | -- | 2,998.94 | -0.0416 | -0.0416 | 0.0001 | 0.0365 | 0.0019 | 10.77 | 0.0305 | -- | -76.61 | -87.67 | -86.56 | -101.98 | -35,950.00 | -32,362.81 | -40,050.00 | -36,853.27 | 6.40 | -- | -- | -- | 669.23 | 57.45 | -39.00 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -68.65m | 689.80m | 10.00 | -- | 6.43 | -- | -- | -4.84 | -4.84 | 0.00 | 7.82 | 0.00 | -- | -- | -- | -32.48 | -26.32 | -47.29 | -29.53 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 52.40 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Navamedic ASA's reporting currency: Norwegian Krone NOK
16.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nordea Investment Management ABas of 31 Oct 2025 | 2.91m | 12.12% |
| Fondita Fund Management Co. Ltd.as of 31 Jan 2026 | 650.00k | 2.71% |
| Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2025 | 457.61k | 1.91% |
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
